BASKING RIDGE, N.J., Dec. 15, 2006 (PRIME NEWSWIRE) -- Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB:MBTG), announces today that while Millennium's flagship patented products Resurgex(r) and Resurgex Plus(r) continue to gain wide acceptance in both the medical and sports markets, its new product, Resurgex Select(tm), which is making inroads in the oncology marketplace, has just been issued a United States Composition Patent for the proprietary formula, as well as a registered trademark.
Resurgex Select(tm) was developed to provide a superior source of high-quality calories as opposed to the corn oil and corn syrup-laden products that are found in the marketplace. In line with Millennium's concept of providing nutritional support throughout the full continuum of oncology care, Select now completes the Resurgex(r) line of products by serving as an acceptable meal supplement and/or replacement for those undergoing medical treatment.
"This product was long overdue and finally serves as an alternative to the nutritionally outdated formulas that exist in the marketplace today," states Carl Germano, RD, CNS, CDN, Millennium's VP of Research and Product Development. "What separates Resurgex Select(tm) from its competitors is the superior sources of carbohydrates, proteins and fats as well as the addition of whey protein, oat fiber, FOS, Omega 3 fats and a concentrated fruit and vegetable extract blend. For those being treated for and suffering from wasting conditions, as in cancer and AIDS, or simply require a high-caloric intake for recovery or repair, Resurgex Select(tm) is the ideal nutritional choice providing 350 high-quality calories per serving."
The newly issued U.S. Patent for Resurgex Select(tm) covers the unique high-caloric composition of ingredients that is distinctly different from its competitors. As with the previous patent issued for Resurgex(r), this additional patent serves to protect the intellectual property of Millennium's new addition to the Resurgex(r) family of products.
About Millennium Biotechnologies, Inc.
Millennium Biotechnologies, Inc. is a research-based pharmaceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products -- Resurgex(r), Resurgex Plus(r) and Resurgex Select(tm) -- are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions. In addition, Resurgex(r) products were developed to address the multiple nutritional needs of professional athletes as well as those who are involved in regular exercise programs. Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly traded company (OTCBB:MBTG). For more information about Millennium Biotechnologies, please call Frank Guarino, Chief Financial Officer, at FGuarino@Milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit http://www.resurgex.com
Millennium plans to file with the Securities and Exchange Commission and mail to its stockholders a proxy statement which will contain information about Millennium, the sale of its assets and the formation and capitalization of RAC Nutrition (the "Proposed Transaction") and related matters. Stockholders are urged to read the proxy statement carefully when it is available, as it will contain important information that stockholders should consider before making a decision about the Proposed Transaction. In addition to receiving the proxy statement from Millennium by mail, stockholders also will be able to obtain the proxy statement, as well as other filings containing information about Millennium, without charge, from the Securities and Exchange Commission's website (http://www.sec.gov). This announcement is neither a solicitation of proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Millennium. Millennium and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Millennium's stockholders with respect to the Proposed Transaction. Information regarding any interests that Millennium's executive officers and directors may have in the Proposed Transaction will be set forth in the proxy statement.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.